[Rinsho ketsueki] The Japanese journal of clinical hematology最新文献_第5页

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.369

引用次数: 0

[Successful treatment with EPOCH followed by mogamulizumab for angioimmunoblastic T-cell lymphoma with myelofibrosis and pure red cell aplasia]. [EPOCH治疗血管免疫母细胞t细胞淋巴瘤伴骨髓纤维化和纯红细胞发育不全的成功治疗]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.24

Ayako Yamamura, Kisato Nosaka, Hiro Tatetsu, Jun-Ichirou Yasunaga

{"title":"[Successful treatment with EPOCH followed by mogamulizumab for angioimmunoblastic T-cell lymphoma with myelofibrosis and pure red cell aplasia].","authors":"Ayako Yamamura, Kisato Nosaka, Hiro Tatetsu, Jun-Ichirou Yasunaga","doi":"10.11406/rinketsu.66.24","DOIUrl":"10.11406/rinketsu.66.24","url":null,"abstract":"The patient was a 70-year-old woman. She visited a doctor for sore throat, facial edema, and lymphadenopathy. Lymph node biopsy was performed, and led to a diagnosis of AITL. When the patient was admitted to our department for treatment, she had severe anemia with Hb 4.2 g/dl, and bone marrow aspiration resulted in a dry tap. Bone marrow biopsy revealed infiltration of tumor cells, a severe decrease in erythroblastic cells, and bone marrow fibrosis. Although lymph node size was reduced by THP-COP, bone marrow biopsy showed residual infiltration of tumor cells. In addition, since low reticulocyte counts and anemia persisted, weekly red blood cell transfusions were required. Therefore, the treatment regimen was changed to EPOCH. After two cycles of EPOCH, anemia improved, and red cell transfusions were no longer required. Bone marrow examination after four cycles showed disappearance of lymphoma cells and no evidence of bone marrow fibrosis or erythroblasts. However, due to residual bone marrow infiltration of lymphoma cells, treatment with mogamulizumab was started. Complete remission was maintained for five years. This indicates that EPOCH and mogamulizumab are treatment options for AITL patients with bone marrow involvement, PRCA, and myelofibrosis.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 1","pages":"24-29"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.18

Kodai Kunisada, Mizuki Ogura, Yuki Oda, Moe Yogo, Tomomi Takei, Kota Sato, Taku Kikuchi, Yu Abe, Nobuhiro Tsukada, Tadao Ishida

{"title":"[Therapy-related myeloid neoplasms with inv (16)(p13.1q22);CBFB::MYH11 during treatment for AL amyloidosis].","authors":"Kodai Kunisada, Mizuki Ogura, Yuki Oda, Moe Yogo, Tomomi Takei, Kota Sato, Taku Kikuchi, Yu Abe, Nobuhiro Tsukada, Tadao Ishida","doi":"10.11406/rinketsu.66.18","DOIUrl":"10.11406/rinketsu.66.18","url":null,"abstract":"[Patient] A 65-year-old man. [History of present illness] An abnormal chest shadow was noted in March of 2011, and hoarseness was observed in November of 2017. Both times, AL amyloidosis was diagnosed by biopsy. The patient was admitted to our department for treatment in March 2018, and received 6 cycles of melphalan plus dexamethasone for systemic AL amyloidosis in May. His condition was good, but a blood test in August 2019 showed white blood cells 50,000/µl and 44.9% blasts in the peripheral blood, leading to a diagnosis of treatment-related acute leukemia (AML with inv (16)(p13.1q22);CBFB::MYH11). He achieved complete remission with standard treatment, but relapsed in May 2020, CNS relapsed in September 2020, CNS relapsed again in July 2021, and CNS relapsed a third time in May 2022. He underwent intensive chemotherapy, whole brain radiation therapy, 13 rounds of intrathecal injection, and five cycles of venetoclax plus azacitidine, but his general condition gradually worsened. He was transferred to best supportive care in November and died in June 2023. [Discussion] Although advances in treatment have extended survival in systemic AL amyloidosis, long-term follow-up for secondary cancer is important for patients with long-term exposure, as in this case.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 1","pages":"18-23"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143384105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Complete response of musculoskeletal chronic GVHD achieved with extracorporeal photopheresis therapy]. [体外光疗治疗肌肉骨骼慢性GVHD的完全缓解]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.228

Toru Ashimoto, Hitoshi Minamiguchi, Masami Kanasaki, Ryo Fukunaga, Kazuki Abe, Mina Kumode, Shiho Nagai, Ai Asai, Masaki Iwasa, Aya Fujishiro, Rie Nishimura, Makoto Murata

{"title":"[Complete response of musculoskeletal chronic GVHD achieved with extracorporeal photopheresis therapy].","authors":"Toru Ashimoto, Hitoshi Minamiguchi, Masami Kanasaki, Ryo Fukunaga, Kazuki Abe, Mina Kumode, Shiho Nagai, Ai Asai, Masaki Iwasa, Aya Fujishiro, Rie Nishimura, Makoto Murata","doi":"10.11406/rinketsu.66.228","DOIUrl":"https://doi.org/10.11406/rinketsu.66.228","url":null,"abstract":"A 48-year-old man with acute myeloid leukemia underwent HLA-matched related donor peripheral blood stem cell transplantation. He developed chronic graft-versus-host disease (cGVHD) of the liver on day 359, which became dependent on cyclosporine and prednisolone. Long-term administration of cyclosporine led to progressive renal dysfunction. Ibrutinib was started, but was stopped due to acute cardiac failure. Mycophenolate mofetil was then started and liver cGVHD improved. The patient developed bacterial pneumonia and COVID-19 during this period. He began to experience limited range of motion in the shoulder joints beyond 2 years after transplantation, and suffered from progressive symptoms. To prevent additional infections due to myelosuppression, drug-induced liver dysfunction, and progression of renal dysfunction, extracorporeal photopheresis (ECP) was chosen to treat musculoskeletal cGVHD. ECP was started on day 1202 and completed 6 months later following the recommended schedule, without severe adverse events. Shoulder joint symptoms completely resolved with ECP, and the cGVHD score in joints decreased from 2 to 0. ECP is considered a promising treatment option for cGVHD patients who are at risk of infection and liver or renal dysfunction.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 4","pages":"228-232"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144032739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.190

引用次数: 0

[Refractory acute monocytic leukemia with cutaneous infiltration complicated by sterile pustules after CPX-351 administration]. [CPX-351给药后伴有皮肤浸润的难治性急性单核细胞白血病并发无菌脓疱]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.165

Takahiro Nishiyama, Takuya Maki, Tomohiro Yamada, Kohei Usui, Yusuke Yamaga, Shoichiro Okazaki

{"title":"[Refractory acute monocytic leukemia with cutaneous infiltration complicated by sterile pustules after CPX-351 administration].","authors":"Takahiro Nishiyama, Takuya Maki, Tomohiro Yamada, Kohei Usui, Yusuke Yamaga, Shoichiro Okazaki","doi":"10.11406/rinketsu.66.165","DOIUrl":"10.11406/rinketsu.66.165","url":null,"abstract":"CPX-351 (Vyxeos®), a liposomal formulation used in the treatment of acute myeloid leukemia, has been associated with cutaneous adverse events, particularly purpura, in previous clinical trials. We present the case of a 73-year-old woman with refractory acute monocytic leukemia and leukemia cutis, who was treated with CPX-351 as salvage induction therapy. Following treatment, the extramedullary lesions resolved; however, some skin lesions developed into pustular eruptions. These pustules appeared during the neutropenic phase, and cultures ruled out infection, leading to the diagnosis of sterile pustulosis. Supportive care, including skin care measures and application of antibiotic ointment, allowed for continued treatment, and the pustules resolved after crusting. To our knowledge, this is the first reported case of sterile pustulosis associated with CPX-351 treatment, highlighting the importance of early detection and appropriate management of skin complications for the successful continuation of therapy.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 3","pages":"165-169"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143775054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.1

引用次数: 0

[Breast implant-associated anaplastic large cell lymphoma that developed 20 years after breast reconstruction and was successfully treated with chemotherapy]. [乳房植入物相关的间变性大细胞淋巴瘤，在乳房重建后20年发生，并通过化疗成功治疗]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.244

Kazuya Manabe, Hiroshi Takahashi, Yasuhiro Uchida, Kengo Suzuki, Naomi Kamei, Mamiko Endo, Masahiko Fukatsu, Takahiro Sano, Kiyohito Hayashi, Motoki Takano, Daisuke Koyama, Satoshi Kimura, Rei Sekine, Hiroyo Meguro, Yasuyuki Kobayashi, Yuko Hashimoto, Takayuki Ikezoe

{"title":"[Breast implant-associated anaplastic large cell lymphoma that developed 20 years after breast reconstruction and was successfully treated with chemotherapy].","authors":"Kazuya Manabe, Hiroshi Takahashi, Yasuhiro Uchida, Kengo Suzuki, Naomi Kamei, Mamiko Endo, Masahiko Fukatsu, Takahiro Sano, Kiyohito Hayashi, Motoki Takano, Daisuke Koyama, Satoshi Kimura, Rei Sekine, Hiroyo Meguro, Yasuyuki Kobayashi, Yuko Hashimoto, Takayuki Ikezoe","doi":"10.11406/rinketsu.66.244","DOIUrl":"https://doi.org/10.11406/rinketsu.66.244","url":null,"abstract":"Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a type of anaplastic large cell lymphoma, that was first described in the revised 4th edition of the WHO Classification of Tumors released in 2017. The textured implants are thought to form bacterial biofilm and cause chronic inflammation, which may be associated with tumorigenesis. We present a 50-year-old woman who had a past medical history of breast reconstruction with the implant 20 years ago. She presented with abdominal distension caused by intraperitoneal lymphadenopathy. She was diagnosed with suspicion of idiopathic multicentric Castleman disease and received pulse therapy with corticosteroid and eight courses of tocilizumab, which resulted in progression of the disease. Positron emission tomography-computed tomography showed new masses in liver and an effusion around the breast implant, and BIA-ALCL was suspected. Pathological examination of the liver tumor and cell blocks made from fluid collected around the implant confirmed the diagnosis of ALCL. Six cycles of brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisolone (BV-CHP) led to complete remission. Her implant was subsequently removed. It is important to keep in mind the possibility of BIA-ALCL when lymphadenopathy is observed in patients with a history of breast reconstruction with textured implants.","PeriodicalId":93844,"journal":{"name":"[Rinsho ketsueki] The Japanese journal of clinical hematology","volume":"66 4","pages":"244-249"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144025769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Erythrocytosis induced by SGLT2 inhibitors]. [SGLT2抑制剂诱导的红细胞增多]。

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.220

Yoko Edahiro

引用次数: 0

[Rinsho ketsueki] The Japanese journal of clinical hematology Pub Date : 2025-01-01 DOI: 10.11406/rinketsu.66.267

引用次数: 0